Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity.
about
Crystal Structures of Ricin Toxin's Enzymatic Subunit (RTA) in Complex with Neutralizing and Non-Neutralizing Single-Chain AntibodiesPrinciples of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agentsProtein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics.A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin.Folding domains within the ricin toxin A subunit as targets of protective antibodiesMechanistic insights into the neutralization of cytotoxic abrin by the monoclonal antibody D6F10.Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection.Immunity to ricin: fundamental insights into toxin-antibody interactions.The need for continued development of ricin countermeasures.Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model.A novel recombinant vaccine protecting mice against abrin intoxication.Isolation of Anti-Ricin Protective Antibodies Exhibiting High Affinity from Immunized Non-Human Primates.Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.A highly emissive fluorescent nucleoside that signals the activity of toxic ribosome-inactivating proteins.Neutralizing monoclonal antibodies against ricin's enzymatic subunit interfere with protein disulfide isomerase-mediated reduction of ricin holotoxin in vitro.Recent advances in the development of vaccines against ricin.Truncated abrin A chain expressed in Escherichia coli: a promising vaccine candidate.Progress and challenges associated with the development of ricin toxin subunit vaccines.Current biodefense vaccine programs and challenges.Structural Analysis of Single Domain Antibodies Bound to a Second Neutralizing Hot Spot on Ricin Toxin's Enzymatic Subunit.Structural analysis of nested neutralizing and non-neutralizing B cell epitopes on ricin toxin's enzymatic subunit.Validation of quantitative ELISAS for measuring anti-Yersinia pestis F1 and V antibody concentrations in nonhuman primate sera.Plant Ribosome-Inactivating Proteins: Progesses, Challenges and Biotechnological Applications (and a Few Digressions).High-Definition Mapping of Four Spatially Distinct Neutralizing Epitope Clusters on RiVax, a Candidate Ricin Toxin Subunit Vaccine.Progress in biological threat agent vaccine development: a repeat-dose toxicity study of a recombinant ricin toxin A-chain (rRTA) 1-33/44-198 vaccine (RVEc) in male and female New Zealand white rabbits.Process development and cGMP manufacturing of a recombinant ricin vaccine: an effective and stable recombinant ricin A-chain vaccine-RVEc™.
P2860
Q27644583-B7616604-240E-478B-8132-345B61FD09C4Q28384852-0A9C1DAF-EC8F-4D2B-9168-57659DE4F906Q30421028-2AF2430A-E118-4B6B-9D09-CE03E1A62E91Q33557719-ED1A4062-95D0-4AE1-951F-1E7BB4D3C733Q34196491-FB0B6696-5B6B-4D64-815D-1FC6D5243F63Q34906649-45DFEBB0-E49B-4EA0-A949-DF1A6954277BQ35229553-B82F9F8A-BAB9-4814-8C2A-47E3B424215CQ35612017-0D2EC34E-E122-4782-A20A-D1D9CC6F7C20Q35866996-CF01419E-001E-42BF-84C8-88040B70F943Q35887201-545BA44A-5EF1-4928-BD99-8E33E8E3933EQ35887567-3206CBFE-88E8-4F3D-B6A1-F98BCA9860E7Q35947693-B2AE2BE1-0FCC-4DE9-AFB0-4E41122E1972Q36911310-3C82372D-E1FD-4AE1-BCB4-B7E9F1273654Q37078677-2DDFDB14-1A46-4E4B-8CEF-41CEE43199EEQ37120906-6C5F2BF7-CB46-48CE-86AA-6DFBD98FA282Q37130978-9DB11325-1922-4C58-8E9E-08EDD5FBD6BCQ37159658-203A21C8-A4A3-4F76-A579-80F60866CD2DQ38783059-C48C3B5E-E29D-4395-99A0-A59287860E3CQ39463803-96706873-09E4-4341-8F37-2734BA80BBE1Q40428974-0869B4FA-6A41-4B5C-BF98-78564E869290Q40682149-5A8C1CE4-FF7B-454B-899F-1B739006AB4DQ41421634-199D5E32-0A6A-4B4E-8636-FB46462E15DCQ41918293-EE756DA3-7E9E-4DA0-B778-82FC9A032B9BQ46281229-EC45CCD5-4EB2-4704-A85F-044FDD5B0C64Q51496298-4E36F85C-40B9-4D95-95AC-1E18550010C8Q54360275-7B1E6CAA-EF60-4870-83EE-6A898B1EC153
P2860
Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Improved formulation of a reco ...... ty and effective antigenicity.
@en
Improved formulation of a reco ...... ty and effective antigenicity.
@nl
type
label
Improved formulation of a reco ...... ty and effective antigenicity.
@en
Improved formulation of a reco ...... ty and effective antigenicity.
@nl
prefLabel
Improved formulation of a reco ...... ty and effective antigenicity.
@en
Improved formulation of a reco ...... ty and effective antigenicity.
@nl
P2093
P1433
P1476
Improved formulation of a reco ...... ty and effective antigenicity.
@en
P2093
Changhong Y Lindsey
John H Carra
Leonard A Smith
Ralph F Tammariello
Richard E Dinterman
Robert W Wannemacher
Rowena D Schokman
P304
P356
10.1016/J.VACCINE.2007.03.011
P407
P577
2007-03-26T00:00:00Z